Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells

Journal of Immunotherapy

Volumn 24, Issue 2, 2001, Pages 162-171

  Hoffmann, T K ^a   Meidenbauer, N ^a   Muller Berghaus J ^a   Storkus, W J ^a   Whiteside, T L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; CD40L; Cross presentation priming; Cytotoxic T cells; Dendritic cells

Indexed keywords

GLYCOPROTEIN GP 39; INTERLEUKIN 12; INTERLEUKIN 15; LACTACYSTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT GAMMA INTERFERON;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; LIGAND BINDING; PRIORITY JOURNAL;

ANTIBODIES; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CD40 LIGAND; CYTOKINES; DENDRITIC CELLS; HEAD AND NECK NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0035120242     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200103000-00011     Document Type: Article

References (40)

1. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
2. A new era for cancer immunotherapy based on genes that encode cancer antigens
3. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
4. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
5. Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells
6. Proinflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
7. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
8. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
9. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
10. Help for cytotoxic-T cell responses is mediated by CD40 signalling
11. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
12. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells
13. CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes
14. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
15. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype
16. High level IL-12 production by human dendritic cells requires 2 signals
17. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-γ and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during interaction with Th cells
18. Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells
19. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines
20. Antigen presentation by MHC class 1 and its regulation by interferon γ
21. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines
22. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and down regulated by tumor necrosis factor alpha
23. Human cytotoxic T cell lines with restricted specificity for squamous cell carcinoma of the head and neck
24. HLA restriction and T cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck
25. + T lymphocytes and human squamous cell carcinoma of the head and neck
26. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines
27. Cancer vaccines
28. Identification of cancer antigens: Impact on development of cancer immunotherapies
29. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTL
30. 5 and CD36, and cross present antigens to cytotoxic T lymphocytes
31. Processing of engulfed apoptotic bodies yields T cell epitopes
32. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function
33. Antigen-presenting cells that phagocytose apoptotic tumor derived cells are potent tumor vaccines
34. Immunogenicity of apoptotic cell in vivo: Role of antigen load, antigen-presenting cells, and cytokines
35. Efficient presentation of phagocytosed cellular fragments on MHC class II products of dendritic cells
36. Natural adjuvants: Endogenous activators of dendritic cells
37. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces maturation of immunostimulatory dendritic cells
38. The induction of tolerance by dendritic cells that have captured apoptotic cells
39. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells
40. Tolerance, danger, and the extended family